Quinn Xue
PharmacokineticsRisk analysis (engineering)CancerPayloadAntibodyConjugateAntibody-drug conjugateTolerabilityDrugContext (language use)Solid tumourLoading ratioDrug penetrationAntibody fragmentsComputer scienceTherapeutic windowCancer researchPotencyMedicine
3Publications
1H-index
2Citations
Publications 2
Newest
#1Mahendra P Deonarain (University of Hertfordshire)
#1Mahendra Deonarain (Imperial College London)H-Index: 19
Last. Quinn XueH-Index: 1
view all 2 authors...
The pharmacokinetic-pharmacodynamic relationship is extremely complex and tumour drug penetration is one key parameter influencing therapeutic efficacy. In the context of antibody-drug conjugates (ADCs), which has undergone many innovation cycles and witnessed many failures, this feature is being addressed by a number of alternative technologies. Immunoglobulin-based ADCs continue to dominate the industrial landscape, but smaller formats offer the promise of more-effective cytotoxic payload deli...
Source
#1Mahendra DeonarainH-Index: 19
#2Gokhan YahiogluH-Index: 24
Last. Quinn XueH-Index: 1
view all 12 authors...
Antibody Drug Conjugates (ADCs) are failing due to 3 critical limitations: Low potency, ineffective solid-tumour penetration and poor tolerability. The industry is full of approaches where full-length Immunoglobulins have been engineered to carry defined numbers of payloads with higher-loadings of less potent payloads appearing to be well-tolerated. However, antibody fragments (e.g. single-chain Fcs-scFvs), which have many advantages including rapid tumour penetration, faster clearance, inexpens...
2 CitationsSource